Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Carboplatin
Related studies linked through entity extraction aliases.
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
- Status
- RECRUITING
- Phase
- PHASE2
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
- Status
- RECRUITING
- Phase
- PHASE1
Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
- Status
- RECRUITING
- Phase
- PHASE2